Drug maker Lupin Thursday announced exclusive launch of Ranolazine extended-release (ER) tablets, indicated for the treatment of chronic angina, in the US market.
Nilesh Gupta, MD of Lupin, spoke to CNBC-TV18 about the recent Ranexa approval and product pipeline.
“This is a great opportunity. First of all, we have a period of exclusivity in this product. We don’t know whether there will be an authorised generic or not, there certainly isn’t an authorised generic today. These are the kinds of opportunities that we have been waiting for quite a few years, the last big one was Glumetza. There is a period of exclusivity, there is more competition that comes in but it is a start of the new products coming, we have Levothyroxine that we will launch very shortly, in the second half we hope to launch the Albuterol MDI as well. I think these will be nice products to come to market,” Gupta said.
Talking about Goa and Pithampur facilities, he said, “We have not specifically guided to put that into numbers at this point of time. Obviously, as both these plants get cleared, that is a nice volume of products that will come to market.”